CHF Solutions Further Expands Commercial Presence in the Middle East with Distribution Arrangement for Israel and Palestine
July 30 2020 - 12:00PM
CHF Solutions (Nasdaq: CHFS) today announced the signing of a distribution agreement with SysteMedic Ltd., covering Israel and Palestine, representing the second distribution partnership in the Middle East region. Ultrafiltration therapy is now available in 16 countries outside the U.S.
Ninety percent of hospitalizations among heart failure patients are due to signs and symptoms of fluid overload,1 and approximately two percent of the Israeli population suffers from heart failure.2 The Aquadex SmartFlow System is a simple, flexible and smart fluid management platform using ultrafiltration to stabilize patients experiencing fluid overload, giving providers the ability to manage their patients’ fluid balance with precision, control and ease.
“CHF Solutions is committed to making ultrafiltration therapy available for patients throughout the world. Our partnership with SysteMedic demonstrates continued execution on that strategy,” said John Erb, chairman and CEO of CHF Solutions. “Subject to regulatory approval, we look forward to working with SysteMedic to make the simple, flexible and smart Aquadex SmartFlow™ system available to patients in Israel and Palestine suffering from fluid overload due to heart failure, cardiovascular surgery and other critical care conditions.”
“We are very excited to work with CHF Solutions to introduce their ultrafiltration technology to Israel and Palestine,” said Arik Yanco, General Manager of SysteMedic. “We believe the Aquadex therapy will make a difference in the quality of lives of patients and look forward to a successful partnership.”
